The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Deposition of Alzheimer's ??-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans
Abstract
Deposition of the beta-amyloid peptide (Abeta) in the brain occurs during normal ageing and is substantially accelerated in patients with Alzheimer's disease. Since Abeta is continuously produced in the brain, it has been suggested that a clearance mechanism should exist to prevent its accumulation and subsequent aggregation. Until now, little attention has been paid to the possible role of P-glycoprotein (P-gp), a member of the ATP binding cassette superfamily of transporter proteins, in the pathogenesis of Alzheimer's disease. A recent study demonstrated that Abeta40 and Abeta42 interact directly with P-gp. We therefore hypothesized that Abeta accumulation in the brain would correlate inversely with the degree of vascular P-gp expression. To study early pathogenetic factors that influence the deposition of Abeta, at routine autopsies, brain tissue samples were taken from 243 non-demented subjects who died between the ages of 50 and 91 years. Vascular P-gp expression and the number of Abeta40- and Abeta42-positive senile plaques were assessed immunohistochemically in the medial temporal lobe. In addition, the apolipoprotein E (apoE) genotypes, as well as multiple drug resistance gene 1 ( ) polymorphisms (exon 2, G-1A; exon 21, G2677T/A; exon 26, C3436T), were also determined for each case. P-gp expression was not correlated with genotypes, but we found a significant inverse correlation between P-gp expression and the deposition of both Abeta40 and Abeta42 in the medial temporal lobe. Our results provide the first evidence in human brain tissue that the accumulation of Abeta may be influenced by the expression of P-gp in blood vessels, and suggest that P-gp may influence the elimination of Abeta from brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Cited by
Cirrito, J. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25247 · Cited by 660
Blood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease
Erickson, M. A., & Banks, W. A. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.135 · Cited by 572
Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease
Yamazaki, Y., & Kanekiyo, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091965 · Cited by 451
Han, L., & Jiang, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.023 · Cited by 358
Blood–Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy
Desai, B. S., Monahan, A. J., Carvey, P. M., & Hendey, B. (2007) · Cell Transplantation · doi:10.3727/000000007783464731 · Cited by 339
Clearing amyloid through the blood-brain barrier
Zlokovic, B. V. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02385.x · Cited by 336
Blood–brain barrier P-glycoprotein function in Alzheimer's disease
van Assema, D. M. E., Lubberink, M., Bauer, M., van der Flier, W. M., Schuit, R. C., Windhorst, A. D., Comans, E. F. I., Hoetjes, N. J., Tolboom, N., Langer, O., et al. (2012) · Brain · doi:10.1093/brain/awr298 · Cited by 318
Delivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
Aβ-degrading enzymes: potential for treatment of Alzheimer disease
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182345e46 · Cited by 265
Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders
Qosa, H., Miller, D. S., Pasinelli, P., & Trotti, D. (2015) · Brain Research · doi:10.1016/j.brainres.2015.07.005 · Cited by 249
Development of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier
Li, J., Zheng, M., Shimoni, O., Banks, W. A., Bush, A. I., Gamble, J. R., & Shi, B. (2021) · Advanced Science · doi:10.1002/advs.202101090 · Cited by 202
Deo, A. K., Borson, S., Link, J. M., Domino, K., Eary, J. F., Ke, B., Richards, T. L., Mankoff, D. A., Minoshima, S., O’Sullivan, F., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.130161 · Cited by 193
Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging
Silverberg, G. D., Messier, A. A., Miller, M. C., Machan, J. T., Majmudar, S. S., Stopa, E. G., Donahue, J. E., & Johanson, C. E. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181f46e25 · Cited by 191
Drug delivery to the brain in Alzheimer's disease: Consideration of the blood–brain barrier
Banks, W. A. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.005 · Cited by 184
Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders
Gil-Martins, E., Barbosa, D. J., Silva, V., Remião, F., & Silva, R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107554 · Cited by 152
Storck, S. E., Hartz, A. M. S., Bernard, J., Wolf, A., Kachlmeier, A., Mahringer, A., Weggen, S., Pahnke, J., & Pietrzik, C. U. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.07.017 · Cited by 143
Self-citationPan, Y., & Nicolazzo, J. A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.009 · Cited by 131
A Role for P-Glycoprotein in Clearance of Alzheimer Amyloid ? -Peptide from the Brain
Wang, W., M. Bodles-Brakhop, A., & W. Barger, S. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160314151012 · Cited by 107
Ito, S., Ohtsuki, S., & Terasaki, T. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.07.006 · Cited by 99
Brenn, A., Grube, M., Jedlitschky, G., Fischer, A., Strohmeier, B., Eiden, M., Keller, M., Groschup, M. H., & Vogelgesang, S. (2014) · Brain Pathology · doi:10.1111/bpa.12069 · Cited by 79
Self-citationHindle, S. J., Munji, R. N., Dolghih, E., Gaskins, G., Orng, S., Ishimoto, H., Soung, A., DeSalvo, M., Kitamoto, T., Keiser, M. J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.026 · Cited by 74
Aging alters mRNA expression of amyloid transporter genes at the blood-brain barrier
Osgood, D., Miller, M. C., Messier, A. A., Gonzalez, L., & Silverberg, G. D. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.05.011 · Cited by 63
Mohamed, L. A., Qosa, H., & Kaddoumi, A. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00040 · Cited by 58
Carrano, A., Snkhchyan, H., Kooij, G., van der Pol, S., van Horssen, J., Veerhuis, R., Hoozemans, J., Rozemuller, A., & de Vries, H. E. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.015 · Cited by 51
Saint-Pol, J., Candela, P., Boucau, M.-C., Fenart, L., & Gosselet, F. (2013) · Brain Research · doi:10.1016/j.brainres.2013.04.008 · Cited by 50
Bachmeier, C., Beaulieu-Abdelahad, D., Crawford, F., Mullan, M., & Paris, D. (2013) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9866-6 · Cited by 39
MicroRNA-27a reduces mutant hutingtin aggregation in an in vitro model of Huntington's disease
Ban, J.-J., Chung, J.-Y., Lee, M., Im, W., & Kim, M. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.05.040 · Cited by 36
Dulin, J. N., Moore, M. L., & Grill, R. J. (2013) · Journal of Neurotrauma · doi:10.1089/neu.2012.2587 · Cited by 24
Metadata
- Authors
- Vogelgesang, S., Cascorbi, I., Schroeder, E., Pahnke, J., Kroemer, H. K., Siegmund, W., Kunert-Keil, C., Walker, L. C., & Warzok, R. W.
- Venue
- Pharmacogenetics
- Published
- 2002-10
- Volume
- 12
- Issue
- 7
- Pages
- 535-541
- ISSN
- 0960-314X (ISSN-L)
- OpenAlex
- W2059841300
- Cited by
- 345
- References
- 1
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
